YIDU TECH (02158), a leading domestic AI healthcare company, has successfully been selected for a national "Unveiling the List and Appointing the Commander" initiative. The project, a multi-modal AI database for gastrointestinal tumor diagnosis and treatment, was jointly submitted with Tongji Hospital affiliated with Huazhong University of Science and Technology. This initiative is part of the Ministry of Industry and Information Technology's 2025 program for innovative artificial intelligence medical devices.
The project aims to establish a high-quality, standardized data platform encompassing the entire lifecycle of gastrointestinal tumors. Based on this platform, an AI-assisted diagnosis and treatment system will be developed, covering processes from screening and typing to efficacy prediction. The ultimate goal is to enhance the early detection rate and treatment precision for gastrointestinal tumors in China and to promote the translation of these research outcomes into practical applications.
The national "Unveiling the List and Appointing the Commander" mechanism is a major innovation strategy designed to accelerate breakthroughs in key core technologies and facilitate the conversion of scientific and technological achievements. This particular task focuses on selecting teams with strong R&D and clinical translation capabilities to collectively address critical challenges, or "bottleneck" problems, in the healthcare sector. Gastrointestinal tumors present a severe clinical challenge in China, characterized by high incidence and mortality rates, low early diagnosis rates, complex choices for personalized treatment plans, and inaccurate prognosis assessments.
The "Standardized Multi-modal Artificial Intelligence Database for Gastrointestinal Tumor Diagnosis and Treatment" project is led by Professor Liao Jiazhi from the Department of Gastroenterology at Tongji Hospital. The core clinical and research team includes Professor Wang Guihua from Gastrointestinal Surgery, Professor Liu Mei from the Department of Gastroenterology, and Professor Chen Yanyan from the Big Data and Artificial Intelligence Office. YIDU TECH will provide comprehensive technical support. The initiative's core involves building a high-quality, standardized multi-modal data foundation to serve as the engine for AI-driven intelligent diagnosis and treatment throughout the entire process.
The technical core of this project lies in "multi-modality" and "standardization." The platform will integrate full-dimensional, full-cycle data, including gastrointestinal endoscopy images, pathological slides, genetic sequencing, and clinical follow-up records. This will create an unprecedented, high-quality, large-scale, and comprehensive data asset library for gastrointestinal tumors, thereby improving the R&D efficiency of medical AI products and technologies in this field.
Building on this foundation, YIDU TECH and Tongji Hospital will form a deeply integrated "innovation consortium." During the project implementation period, the consortium plans to aggregate and process tens of thousands of high-quality case data points. It will develop AI algorithm models for several key scenarios, including early screening, precise typing, efficacy prediction, and recurrence risk assessment for gastrointestinal tumors, and will promote their transformation into medical device products and clinical applications.
Furthermore, the collaboration will involve formulating multiple clinical application guidelines and industry standards related to AI diagnosis and treatment for gastrointestinal tumors. Based on actual clinical needs, they will conduct R&D and transformation of AI products for gastrointestinal tumor diagnosis and treatment. The partnership will also focus on cultivating interdisciplinary talent with backgrounds in both clinical medicine and data science. These measures are considered significant for helping China gain a leading position in global technology and rule-making in this field.
As a pioneer in the AI healthcare sector, YIDU TECH has accumulated extensive experience in data governance, knowledge graphs, and multi-modal analysis. As of September 30, 2025, the company has served 127 renowned medical institutions across China. Its "AI Medical Brain," YiduCore, has processed and analyzed nearly 7 billion authorized medical records, covering a cooperative hospital network of over 10,000 institutions. This provides a solid data foundation and clinical insights for the training, optimization, and real-world application of AI models.
Industry analysis suggests that this collaboration is a vivid example of an innovative model driven by clinical demand, powered by AI R&D, and characterized by industry-academia-research-application synergy. It is expected to help enhance the overall diagnosis and treatment level for gastrointestinal tumors in China, offering patients more precise, efficient, and accessible medical services, thereby significantly improving their quality of life.
YIDU TECH stated that the company will continue to promote the deep integration of cutting-edge technology and clinical needs, fully advancing the project's objectives to push gastrointestinal tumor diagnosis and treatment towards greater intelligence. The data governance standards, AI R&D pathways, and clinical application paradigms explored in this project are expected to be replicable and promotable to other major disease areas, contributing to the "Healthy China 2030" initiative.